XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Income Statements (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue $ 2,268 $ 2,104 $ 6,638 $ 6,306
Cost of revenue 1,385 1,320 4,095 3,951
Gross profit 883 784 2,543 2,355
Selling, general and administrative expenses 474 445 1,437 1,404
Research and development expenses 52 55 166 172
Restructuring and asset impairment charges 23 4 70 37
Operating income 334 280 870 742
Interest expense (6) (10) (23) (35)
Other non-operating income, net 6 1 13 11
Loss on sale of businesses (37) (2) (47) (6)
Income before taxes 297 269 813 712
Income tax expense (71) (52) (196) (148)
Net income 226 217 617 564
Net loss attributable to non-controlling interests 1 0 5 0
Net income attributable to Xylem $ 227 $ 217 $ 622 $ 564
Earnings per share:        
Basic (usd per share) $ 0.93 $ 0.89 $ 2.56 $ 2.33
Diluted (usd per share) $ 0.93 $ 0.89 $ 2.55 $ 2.32
Weighted average number of shares:        
Basic (in shares) 243,454 242,932 243,319 242,453
Diluted (in shares) 244,091 243,750 243,910 243,437
Revenue from products        
Revenue $ 1,867 $ 1,744 $ 5,487 $ 5,236
Cost of revenue 1,109 1,047 3,279 3,147
Revenue from services        
Revenue 401 360 1,151 1,070
Cost of revenue $ 276 $ 273 $ 816 $ 804